Cambridge, MA, United States of America

Matthew Chiocco

This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: Generation Bio Co.. Active years: 2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Matthew Chiocco. Retrieved from https://idiyas.com/inventor/matthew-chiocco

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 1 

% Patents Active = 100.0

Average Co-Inventor Count = 4.0

ph-index = 1


Company Filing History:


Years Active: 2025

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Matthew Chiocco: Innovator in Gene Therapy

Introduction

Matthew Chiocco is a prominent inventor based in Cambridge, MA (US). He has made significant contributions to the field of gene therapy, particularly in the development of non-viral DNA vectors. His work focuses on innovative solutions for expressing phenylalanine hydroxylase (PAH) therapeutics, which are crucial for treating genetic disorders such as Phenylketonuria (PKU).

Latest Patents

Matthew Chiocco holds 1 patent for his invention titled "Non-viral DNA vectors and uses thereof for expressing phenylalanine hydroxylase (PAH) therapeutics." This patent describes ceDNA vectors that have a linear and continuous structure designed for the delivery and expression of a transgene. The ceDNA vectors include an expression cassette flanked by two ITR sequences, encoding the PAH protein. Additionally, some ceDNA vectors incorporate cis-regulatory elements, including regulatory switches. The patent also outlines methods and cell lines for reliable gene expression of PAH protein in vitro, ex vivo, and in vivo using these ceDNA vectors.

Career Highlights

Matthew Chiocco is currently associated with Generation Bio Co., where he continues to advance his research in gene therapy. His innovative approach to developing ceDNA vectors has the potential to revolutionize treatment methods for diseases related to PAH deficiency.

Collaborations

Matthew collaborates with notable colleagues, including Douglas Anthony Kerr and Phillip Samayoa, who contribute to his research endeavors and the advancement of gene therapy technologies.

Conclusion

Matthew Chiocco's work in developing non-viral DNA vectors represents a significant advancement in gene therapy, offering new hope for patients with genetic disorders. His contributions to the field are paving the way for innovative treatment options.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…